Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ave-CRT: Avelumab + Chemoradiotherapy in Metastatic Esophageal SCC
NCT03800953Phase 2Unknown
- Sponsor
- National Taiwan University Hospital
- Start
- Mar 2019
- Primary completion
- Dec 2021
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of avelumab in Esophageal Squamous Cell Carcinoma (ESCC), sponsored by National Taiwan University Hospital. Primary endpoint: Overall Radiographic Response at 6 months. Status: unknown.
02
Drugs
avelumab
03
Conditions
Esophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on NCT03800953.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03800953.